CD22 CAR T-cell therapy: new hope for patients with large B-cell lymphoma
- PMID: 38996464
- DOI: 10.1016/S0140-6736(24)00815-8
CD22 CAR T-cell therapy: new hope for patients with large B-cell lymphoma
Conflict of interest statement
M-LS reports consultancy for Gilead and Takeda; and meeting attendance support from Janssen and Sobi. PD reports consultancy for AbbVie, AstraZeneca, Beigene, BMS, Gilead, and Miltenyi (all to institution); speakers bureau for AbbVie, AstraZeneca, BeiGene, BMS, Gilead, Riemser, and Roche (all to institution); research support from Riemser (all to institution); meeting attendance support from Beigene and Gilead; participation on a data safety monitoring board for Novartis; and is the current chairman of the German Working Group for Haematopoietic Stem Cell Transplantation and Cellular Therapy.
Comment on
-
CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study.Lancet. 2024 Jul 27;404(10450):353-363. doi: 10.1016/S0140-6736(24)00746-3. Epub 2024 Jul 9. Lancet. 2024. PMID: 38996463 Free PMC article. Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
